HeartSciences
Southlake, Texas, United States · Biotechnology, Healthcare, Medical Equipment Manufacturing
HeartSciences Inc. is a medical technology company focused on developing innovative solutions for cardiac diagnostics. The company aims to improve the detection and management of heart diseases through advanced technologies. HeartSciences is dedicated to enhancing patient outcomes and providing healthcare professionals with effective tools. The firm operates in Southlake, Texas.
Key facts
- Headquarters
- Southlake, Texas, United States
- Employees
- 15
- Industries
- Biotechnology, Healthcare, Medical Equipment Manufacturing
- Status
- Public (HSCS)
- Website
- heartsciences.com
- Company page
Recent activity at HeartSciences
- : SEC 8-K (8.01):
- : SEC 8-K (7.01): On October 6, 2026, HeartSciences Inc. announced that the U.S. Food and Drug Administration granted 510(k) clearance for its MyoVista® wavECG™ device as a 12-lead resting electrocardiograph. This clearance is expected to enhance the company's product offerings in the cardiology market. The FDA approval positions HeartSciences to potentially increase its market share and improve patient diagnosis capabilities. This filing contains the press release as Exhibit 99.1 and highlights the significance of this regulatory achievement for the company's future prospects.
- : SEC 8-K (1.01): HeartSciences Inc. entered into Amendment No. 8 to its Loan and Security Agreement with Front Range Ventures LLC on September 29, 2026, which allows the Company to borrow $500,000 under new terms. The amendment extends the maturity date of the related promissory note to either two business days following the closing of a proposed business combination with Fortitude Mining Holdings, Inc. or January 29, 2027. The accrued interest payment terms were also revised, requiring a payment of accrued interest by September 30, 2026, with the option for the company to repay parts of the principal before the new maturity date. The agreement is significant as it not only extends the borrowing time frame but also refines the repayment structure, thus impacting the company's liquidity management during its pending business combination.
- : SEC 8-K (8.01): On September 16, 2026, Fortitude's Board of Directors approved the appointment of Jaime Leverton as Chief Executive Officer, effective September 21, 2026. Concurrently, Andrea Childs is resigning as a Board member effective immediately and will also step down from her position as Chief Executive Officer on the same day, transitioning to Chief Operating Officer. This management change is significant as it comes in the context of a proposed business combination involving HeartSciences and Fortitude. Leverton is also expected to join the Board of Directors of HeartSciences, which will be renamed Fortitude Mining Group, Inc., following the closing of the Proposed Transaction.
- : SEC 8-K (2.02): On September 15, 2026, HeartSciences Inc. disclosed significant updates regarding their financial and operating results for the quarter ending July 31, 2026, including details of a merger agreement with Fortitude Mining Holdings, Inc., established on June 23, 2026. The Proposed Transaction is an all-stock merger wherein HeartSciences will combin with Fortitude, a digital asset mining platform. This merger is expected to enhance HeartSciences' operational capabilities and market presence in the digital assets sector. The strategic implications of this merger could lead to diversification of HeartSciences' business portfolio and improved financial stability as they enter the digital asset space.
- : SEC 8-K (7.01):
- : SEC 8-K (7.01): On August 12, 2026, HeartSciences Inc. completed the sale and issuance of 411,522 shares of its common stock to Fortitude Mining Holdings, Inc. in a private placement at a price of $2.43 per share. This transaction is part of a previously reported proposed business combination with Fortitude, which is expected to enhance HeartSciences' strategic position in the market. The press release detailing this transaction was issued on August 19, 2026, highlighting the significance of this development for both companies. The financial implications of this transaction are notable, as it indicates robust interest in HeartSciences' equity, potentially impacting future capital and operational strategies.
- : HeartSciences Secures Funding from Fortitude Mining Holdings
- : SEC 8-K (1.01):
- : HeartSciences to merge with Fortitude Mining Holdings
HeartSciences funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $1.0M |
| Dec 2023 | Seed | $935K |
| Dec 2023 | Seed | $1.6M |
| Sep 2023 | Seed | $1.0M |
| Dec 2021 | Seed | $2.0M |
Leadership
- Brian Szymczak, Director
- John Owen, Director
- Patrick Kanouff, Director
- John Adams, Director
Verified email and direct lines for HeartSciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
HeartSciences files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Oct 2027.
HeartSciences in the news
- HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis - Investing News Network (Jun 05, 2025)
- Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets - Business Wire (Jun 23, 2026)
- HeartSciences Appoints David Wells to its Board of Directors - citybiz (Jan 04, 2023)
- HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining - GlobeNewswire (Oct 21, 2026)
- MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark - dicardiology.com (Jul 27, 2023)
- HeartSciences Surges on Planned Merger With Zcash Mining Platform Fortitude | HSCS Stock News - Quiver Quantitative (Jun 23, 2026)
- HeartSciences Inc. (HSCS) Company Information - Simply Wall St (Apr 04, 2024)
- HeartSciences Appoints Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board - citybiz (Feb 26, 2024)
Companies similar to HeartSciences
- Glucotrack · Biotechnology, Healthcare
- NEXTSTEP ROBOTICS · Biotechnology, Healthcare
- Kernal Biologics · Biotechnology, Healthcare
- Galectin · Biotechnology, Healthcare
- CalciMedica · Biotechnology, Healthcare
About HeartSciences: questions and answers
What does HeartSciences do?
HeartSciences Inc. is a medical technology company focused on developing innovative solutions for cardiac diagnostics. The company aims to improve the detection and management of heart diseases through advanced technologies. HeartSciences is dedicated to enhancing patient outcomes and providing healthcare professionals with effective tools. The firm operates in Southlake, Texas.
Where is HeartSciences headquartered?
HeartSciences is headquartered in Southlake, Texas, United States.
How many employees does HeartSciences have?
HeartSciences has about 15 employees.
Has HeartSciences raised funding?
Yes. Fundz has recorded 5 funding events for HeartSciences. The most recent, Post-IPO Equity of $1.0M, was in Aug 2026.
What is the latest news on HeartSciences?
On Nov 06, 2026, SEC 8-K (8.01):
Is HeartSciences a public company?
Yes. HeartSciences is publicly traded under the ticker HSCS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy